Citadel Advisors
VTVT icon

Citadel Advisors’s vTv Therapeutics VTVT Stock Holding History

Citadel Advisors’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-606
Closed -$19.6K – 15313
2023
Q1 		$19.6K Sell
606
-616
-50% -$20.9K ﹤0.01% 13082
2022
Q4 		$31.9K Buy
1,222
+397
+48% +$13.1K ﹤0.01% 12664
2022
Q3 		$32K Sell
825
-107
-11% -$4.21K ﹤0.01% 11875
2022
Q2 		$28K Buy
+932
New +$23.9K ﹤0.01% 12268
2022
Q1 		– Sell
-2,353
Closed -$94K – 14677
2021
Q4 		$94K Sell
2,353
-880
-27% -$47.2K ﹤0.01% 12780
2021
Q3 		$198K Buy
3,233
+37
+1% +$2.79K ﹤0.01% 11996
2021
Q2 		$291K Sell
3,196
-1,306
-29% -$132K ﹤0.01% 11347
2021
Q1 		$508K Buy
+4,502
New +$442K ﹤0.01% 9646
2020
Q4 		– Sell
-363
Closed -$26K – 11587
2020
Q3 		$26K Buy
+363
New +$31.9K ﹤0.01% 9806
2018
Q3 		– Sell
-265
Closed -$16K – 9734
2018
Q2 		$16K Buy
+265
New +$19.6K ﹤0.01% 8685
2016
Q1 		– Sell
-769
Closed -$209K – 8055
2015
Q4 		$209K Buy
769
+76
+11% +$21.3K ﹤0.01% 5751
2015
Q3 		$181K Buy
+693
New +$241K ﹤0.01% 6276

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SQA
Simon Quick Advisors Morristown, New Jersey $2.19B AUM 17.29% 1-Year Est. Return

Citadel Advisors's VTVT Position: Q2 2023 in Review

Citadel Advisors sold out of vTv Therapeutics (VTVT) in Q2 2023, closing a stake of 606 shares — an estimated $19.6K sold.

Citadel Advisors first reported a position in VTVT in Q3 2015 and held it in 12 quarters. The position peaked at $508K in Q1 2021. 20 funds tracked by Wall St. Rank hold VTVT as of Q2 2023.

  • Citadel Advisors reported no remaining vTv Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 606 vTv Therapeutics shares in Q2 2023, an estimated $19.6K.
  • Citadel Advisors first reported a position in vTv Therapeutics in Q3 2015 and held it in 12 quarters.
  • Citadel Advisors's vTv Therapeutics position peaked at $508K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.